Valuation: Alumis Inc.

Market Cap 757M 675M 617M 562M 1.06B 71.56B 1.09B 7.41B 2.96B 37.9B 2.84B 2.78B 120B P/E 2026 *
-1.79x
P/E 2027 * -2.08x
Enterprise Value 41.2M 36.71M 33.58M 30.58M 57.64M 3.89B 59.19M 403M 161M 2.06B 155M 151M 6.51B EV / Sales 2026 *
6.58x
EV / Sales 2027 * 10x
Free-Float
96.45%
Yield 2026 *
-
Yield 2027 * -
1 day+0.17%
1 week-11.96%
Current month-11.96%
1 month-14.50%
3 months-78.69%
6 months-76.76%
Current year-39.29%
1 week 5.75
Extreme 5.75
6.81
1 month 5.75
Extreme 5.75
7.31
Current year 5.75
Extreme 5.75
31.35
1 year 4.4
Extreme 4.4
31.35
3 years 2.76
Extreme 2.7601
31.35
5 years 2.76
Extreme 2.7601
31.35
10 years 2.76
Extreme 2.7601
31.35
Manager TitleAgeSince
Chief Executive Officer 61 23/09/2021
Director of Finance/CFO 60 01/05/2022
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Director/Board Member 60 01/06/2021
Chairman 61 23/09/2021
Director/Board Member 55 01/05/2022
Date Insider Type Main position Quantity % Market Cap. Importance
9/8/26 A
Samsara BioCapital LLC
SellCompany -642,712 0.5207%
9/4/26 A Other

Director

0 0%
8/3/26 A Sell

Chief Technology Officer

-2,447 0.0020%
Change 5-day change 1-year change 3-year change Capi.($)
+0.34%-11.96%+25.53% - 757M
-4.83%+2.88%+55.87%+69.12% 69.4B
-0.69%+0.20%+9.68%+75.14% 57.24B
-1.19%+3.07%+24.91%+100.36% 57.62B
+1.85%+1.17%+28.27%+36.32% 43.65B
+4.64%+9.81%+22.35%+107.33% 44.03B
+3.84%-3.21%+201.66%+759.61% 38.08B
-1.86%+11.46%+26.67%+61.40% 36.31B
-3.56%-10.30%+87.90%+75.27% 32.61B
-2.18%+5.68%+36.21%-0.69% 25.47B
Average -0.42%+0.50%+51.91%+142.65% 40.52B
Weighted average by Cap. -0.66%+2.40%+50.69%+135.46%

Financials

2026 *2027 *
Net sales 6.26M 5.58M 5.1M 4.65M 8.76M 592M 9M 61.31M 24.52M 313M 23.5M 23M 989M 24.33M 21.68M 19.83M 18.06M 34.05M 2.3B 34.97M 238M 95.28M 1.22B 91.34M 89.38M 3.84B
Net income -427M -381M -348M -317M -598M -40.38B -614M -4.18B -1.67B -21.39B -1.6B -1.57B -67.48B -409M -364M -333M -303M -572M -38.62B -587M -4B -1.6B -20.45B -1.53B -1.5B -64.54B
Net Debt -716M -638M -584M -531M -1B -67.66B -1.03B -7.01B -2.8B -35.83B -2.69B -2.63B -113B -514M -458M -419M -381M -719M -48.56B -738M -5.03B -2.01B -25.72B -1.93B -1.89B -81.16B
Projected Income Statement - Annual - Alumis Inc.
Logo Alumis Inc.
Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of envudeucitinib for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.
Employees
238
Date Price Change Volume
06/11/26 $5.960 +1.88% 145,982
05/11/26 $5.850 -10.69% 1,950,463
04/11/26 $6.550 +0.77% 1,290,062
03/11/26 $6.500 +1.88% 2,566,618
02/11/26 $6.380 -5.20% 1,430,150
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Alumis Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
5.850USD
Average target price
31.12USD
Spread / Average Target
+432.05%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Alumis Inc.
  1. Stock Market
  2. Stocks
  3. ALMS Stock